The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
On June 4, ADC Therapeutics announced positive Phase 3 LOTIS-5 trial results for its ZYNLONTA therapy in treating lymphoma. The study showed an improved progression-free survival of 6.1 months compared to 4.7 months for standard immunochemotherapy. Jefferies analysts set a price target of $84.00 for the company's stock. On the same day, Amneal Pharmaceuticals received US FDA approval for its ready-to-use romidepsin injection, granting it 180 days of market exclusivity. On June 5, shares of the Nasdaq-listed company rose 8.7% to $5.89 following the announcement.